Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Zanidatamab-hrii

Placeholder slot
 (ZAN-ih-DA-tuh-mab)

Zanidatamab-hrii works by binding to two specific sites on the HER2 protein, which is found in high levels on the surface of some cancer cells. This binding damages the HER2 protein and lowers the amount of it on the cell surface. Zanidatamab-hrii also helps the immune system kill cancer cells. These combined actions may slow or stop the growth of HER2-positive cancer cells. Zanidatamab-hrii is a type of targeted therapy called a bispecific HER2-directed antibody.

US Brand Name(s)
Ziihera
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Zanidatamab-hrii is approved to treat adults with:

Zanidatamab-hrii is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Zanidatamab-hrii is also being studied in the treatment of other types of cancer.

More About Zanidatamab-hrii

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Zanidatamab-hrii - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email